Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Other Non-current Assets
Long-term assets not reported separately.
Forte Biosciences, Inc.NASDAQ: FBRX
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets rises 1038.1% from a year ago
Other non-current assets stood at $2M at the end of Q1 FY2026, up 1038.1% from a year earlier and down 2.8% from the prior quarter. Over 3 fiscal years it compounded at +61.9% a year.
Context
- Other non-current assets amounted to 3.0% of total assets at the end of Q1 FY2026, up 2.6 pp from a year earlier.
- Other non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +1038.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 2.06M USD
- Year-over-year change
- +1393.5%
- 4-year CAGR
- +27.3%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.06M | +1393.5% |
| FY2024 | 2024-12-31 | 138K | -74.6% |
| FY2023 | 2023-12-31 | 544K | +11.9% |
| FY2022 | 2022-12-31 | 486K | -38.2% |
| FY2021 | 2021-12-31 | 786K | — |
Other Non-current Assets vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +1038.1% is the highest of 9, against a peer median of -1.8%.
- Other non-current assets amounts to 3.0% of total assets for FBRX, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $10.05M USD | -1.7% | -57.4% | 3.5% | |
| Mar 2026 | $4.32M USD | -40.4% | +33.9% | 1.2% | |
| Mar 2026 | $2.22M USD | -65.2% | -34.3% | 0.9% | |
| Mar 2026 | $2M USD | +1038.1% | +61.9% | 3.0% | |
| Mar 2026 | $1.94M USD | -1.9% | +9.2% | 1.2% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $1.7M USD | +31.0% | -19.6% | 7.5% |
| Mar 2026 | $844K USD | +228.4% | -26.6% | 1.7% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $391.84K USD | +67.1% | — | 4.4% |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | CHF 0 CHF | — | — | 0.0% | |
| Peer median (excluding FBRX) | — | -1.8% | -23.1% | 1.2% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.